Telomerase Inhibitors
AssigneeGeron Corporation
InventorsFederico C. A. Gaeta, Adam Antoni Galan, Elaine C. Stracker
Life of this patent
Estimating the term…
Loading patent…
AssigneeGeron Corporation
InventorsFederico C. A. Gaeta, Adam Antoni Galan, Elaine C. Stracker
Estimating the term…
Methods and compositions for treating cancer and other diseases in which inhibition of telomerase activity can ameliorate disease symptoms or prevent or treat the disease relate to compounds that are derivatives of benzob!thiophenes. Such compounds are characterized by the following structure: ##STR1## In this compound, R.sub.1 is selected from the group consisting of --OR.sub.7, --NR.sub.8 R.sub.9, --NHNR.sub.10 R.sub.11, --NHNHC(X.sub.2)NHR.sub.12, --NHSO.sub.2 NR.sub.8 R.sub.9, --NHNHC(O)R.sub.12, --NHNHSO.sub.2 R.sub.12 and --NHC(O)NR.sub.8 R.sub.9. R.sub.7 -R.sub.12 are selected independently from the group consisting of hydrogen, alkyl, aryl, aralkyl, heteroaryl and heteroaralkyl. X.sub.1 and X.sub.2 are selected independently from the group consisting of oxygen and sulfur. R.sub.2 is hydrogen or halogen. R.sub.3 -R.sub.6 are selected independently from the group consisting of hydrogen, halogen, hydroxyl, --NR.sub.8 R.sub.9, nitro, cyano, alkoxyl, lower alkyl, aryl and aryloxyl.
A telomerase inhibiting compound having the structure:
The compound of 5, wherein R.sub.13 -R.sub.17 are selected independently from the group consisting of hydrogen, chloro, bromo, fluoro, methyl, trifluoromethyl, dimethylamino, 4-methylphenylthio, 4-nitrophenylthio and methylthio.
The compound of 11, wherein R.sub.13 -R.sub.17 are selected independently from the group consisting of hydrogen, chloro, bromo, fluoro, methyl, trifluoromethyl, dimethylamino, 4-methylphenylthio, 4-nitrophenylthio and methylthio.
A composition for treating cancer, comprising a therapeutically effective amount of a compound having the structure shown below in a pharmaceutically acceptable carrier:
Dependencies are inferred from the claim text.